Post-Operative Pain - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 187
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PB52535144BEN
Leaflet:

Download PDF Leaflet

Post-Operative Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Post-Operative Pain - Pipeline Review, H2 2016’, provides an overview of the Post-Operative Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
  • The report reviews pipeline therapeutics for Post-Operative Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Post-Operative Pain therapeutics and enlists all their major and minor projects
  • The report assesses Post-Operative Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Post-Operative Pain
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Post-Operative Pain Overview
Therapeutics Development
Pipeline Products for Post-Operative Pain - Overview
Post-Operative Pain - Therapeutics under Development by Companies
Post-Operative Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Post-Operative Pain - Products under Development by Companies
Post-Operative Pain - Companies Involved in Therapeutics Development
AcelRx Pharmaceuticals, Inc.
Adynxx, Inc.
AngioChem Inc.
AskAt Inc.
Boehringer Ingelheim GmbH
Cara Therapeutics, Inc.
Colby Pharmaceutical Company
Cytogel Pharma, LLC
Dompe Farmaceutici S.p.A.
DURECT Corporation
Echo Pharmaceuticals B.V.
Fujimoto Pharmaceutical Corporation
Galleon Pharmaceuticals
Grunenthal GmbH
GW Pharmaceuticals Plc
Heron Therapeutics, Inc.
Immupharma Plc
Innocoll AG
INSYS Therapeutics, Inc.
Laboratorios Del Dr. Esteve S.A.
Lipocure Ltd.
Liquidia Technologies, Inc.
Medtronic plc
Orbis Biosciences, Inc.
Orion Oyj
Pacira Pharmaceuticals, Inc.
PainReform Ltd.
Pharmazz, Inc.
PhytoHealth Corporation
Proteus SA
Recro Pharma, Inc.
Relmada Therapeutics, Inc.
Serina Therapeutics, Inc.
SteadyMed Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
The Medicines Company
Trevena, Inc.
Post-Operative Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(bupivacaine hydrochloride + meloxicam) - Drug Profile
AM-4 - Drug Profile
ANG-2002 - Drug Profile
ARX-04 - Drug Profile
AYX-1 - Drug Profile
BI-1026706 - Drug Profile
bupivacaine hydrochloride - Drug Profile
bupivacaine hydrochloride - Drug Profile
bupivacaine hydrochloride - Drug Profile
bupivacaine hydrochloride - Drug Profile
bupivacaine hydrochloride ER - Drug Profile
bupivacaine hydrochloride SR - Drug Profile
buprenorphine hydrochloride - Drug Profile
CPC-123 - Drug Profile
CR-4056 - Drug Profile
Cyt-1010 - Drug Profile
dexmedetomidine hydrochloride - Drug Profile
DF-2755A - Drug Profile
difelikefalin - Drug Profile
difluprednate XR - Drug Profile
dronabinol - Drug Profile
Drug for Post Operative Pain - Drug Profile
ECP-1014 - Drug Profile
fadolmidine hydrochloride - Drug Profile
fentanyl - Drug Profile
GAL-044 - Drug Profile
grapiprant - Drug Profile
IPP-102199 - Drug Profile
ketamine hydrochloride - Drug Profile
ketorolac tromethamine - Drug Profile
levorphanol tartrate ER - Drug Profile
MDT-10013 - Drug Profile
meloxicam - Drug Profile
meloxicam ER - Drug Profile
meloxicam ER - Drug Profile
MR-309 - Drug Profile
nabiximols - Drug Profile
nalbuphine hydrochloride - Drug Profile
neosaxitoxin - Drug Profile
oliceridine - Drug Profile
PMZ-2010 - Drug Profile
RBM-004 - Drug Profile
ropivacaine - Drug Profile
ropivacaine ER - Drug Profile
SER-226 - Drug Profile
Small Molecule for Post-Operative Pain - Drug Profile
sufentanil citrate - Drug Profile
tapentadol hydrochloride - Drug Profile
tramadol hydrochloride - Drug Profile
tramadol hydrochloride ER - Drug Profile
URB-937 - Drug Profile
VVZ-149 - Drug Profile
Post-Operative Pain - Dormant Projects
Post-Operative Pain - Discontinued Products
Post-Operative Pain - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Post-Operative Pain, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016
Post-Operative Pain - Pipeline by Adynxx, Inc., H2 2016
Post-Operative Pain - Pipeline by AngioChem Inc., H2 2016
Post-Operative Pain - Pipeline by AskAt Inc., H2 2016
Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
Post-Operative Pain - Pipeline by Colby Pharmaceutical Company, H2 2016
Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H2 2016
Post-Operative Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
Post-Operative Pain - Pipeline by DURECT Corporation, H2 2016
Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016
Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corporation, H2 2016
Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H2 2016
Post-Operative Pain - Pipeline by Grunenthal GmbH, H2 2016
Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016
Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H2 2016
Post-Operative Pain - Pipeline by Immupharma Plc, H2 2016
Post-Operative Pain - Pipeline by Innocoll AG, H2 2016
Post-Operative Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016
Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
Post-Operative Pain - Pipeline by Lipocure Ltd., H2 2016
Post-Operative Pain - Pipeline by Liquidia Technologies, Inc., H2 2016
Post-Operative Pain - Pipeline by Medtronic plc, H2 2016
Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H2 2016
Post-Operative Pain - Pipeline by Orion Oyj, H2 2016
Post-Operative Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016
Post-Operative Pain - Pipeline by PainReform Ltd., H2 2016
Post-Operative Pain - Pipeline by Pharmazz, Inc., H2 2016
Post-Operative Pain - Pipeline by PhytoHealth Corporation, H2 2016
Post-Operative Pain - Pipeline by Proteus SA, H2 2016
Post-Operative Pain - Pipeline by Recro Pharma, Inc., H2 2016
Post-Operative Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016
Post-Operative Pain - Pipeline by Serina Therapeutics, Inc., H2 2016
Post-Operative Pain - Pipeline by SteadyMed Therapeutics, Inc., H2 2016
Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Post-Operative Pain - Pipeline by The Medicines Company, H2 2016
Post-Operative Pain - Pipeline by Trevena, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Post-Operative Pain - Dormant Projects, H2 2016
Post-Operative Pain - Dormant Projects (Contd..1), H2 2016
Post-Operative Pain - Dormant Projects (Contd..2), H2 2016
Post-Operative Pain - Dormant Projects (Contd..3), H2 2016
Post-Operative Pain - Dormant Projects (Contd..4), H2 2016
Post-Operative Pain - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Post-Operative Pain, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ocular Pain - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 70 pages

Ask Your Question

Post-Operative Pain - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: